End-Stage Renal Disease in African Americans With Lupus Nephritis Is Associated With APOL1 by Freedman, Barry I. et al.
End-Stage Renal Disease in African Americans With Lupus
Nephritis Is Associated With APOL1
Barry I. Freedman, MD1, Carl D. Langefeld, PhD1, Kelly K. Andringa, PhD, MBA2, Jennifer
A. Croker, PhD, MA2, Adrienne H. Williams, MA1, Neva E. Garner, MPH2, Daniel J.
Birmingham, PhD3, Lee A. Hebert, MD3, Pamela J. Hicks, BS1, Mark S. Segal, MD, PhD4,
Jeffrey C. Edberg, PhD2, Elizabeth E. Brown, PhD, MPH2, Graciela S. Alarcón, MD, MPH2,
Karen H. Costenbader, MD, MPH5, Mary E. Comeau, MA1, Lindsey A. Criswell, MD, MPH,
DSc6, John B. Harley, MD, PhD7, Judith A. James, MD, PhD8, Diane L. Kamen, MD, MSCR9,
S. Sam Lim, MD, MPH10, Joan T. Merrill, MD11, Kathy L. Sivils, PhD11, Timothy B. Niewold,
MD12, Neha M. Patel, MD13, Michelle Petri, MD, MPH14, Rosalind Ramsey-Goldman, MD,
DrPH15, John D. Reveille, MD16, Jane E. Salmon, MD17, Betty P. Tsao, PhD18, Keisha L.
Gibson, MD, MPH19, Joyce R. Byers, RN1, Anna K. Vinnikova, MD20, Janice P. Lea, MD,
MSc10, Bruce A. Julian, MD2, and Robert P. Kimberly, MD2 on behalf of the Lupus
Nephritis–End-Stage Renal Disease Consortium
1Wake Forest School of Medicine, Winston-Salem, North Carolina 2University of Alabama at
Birmingham 3The Ohio State University Wexner Medical Center, Columbus 4University of Florida,
Gainesville 5Brigham and Women’s Hospital, Boston, Massachusetts 6University of California,
San Francisco 7Cincinnati Children’s Hospital Medical Center and Cincinnati VA Medical Center,
Cincinnati, Ohio 8Oklahoma Medical Research Foundation and University of Oklahoma Health
Sciences Center, Oklahoma City 9Medical University of South Carolina, Charleston 10Emory
University School of Medicine, Atlanta, Georgia 11Oklahoma Medical Research Foundation,
Oklahoma City 12Mayo Clinic, Rochester, Minnesota 13State University of New York Downstate
Medical Center, Brooklyn 14Johns Hopkins School of Medicine, Baltimore, Maryland
15Northwestern University, Feinberg School of Medicine, Chicago, Illinois 16University of Texas
© 2014, American College of Rheumatology
Address correspondence to Barry I. Freedman, MD, or Carl D. Langefeld, PhD, Wake Forest School of Medicine, Medical Center
Boulevard, Winston-Salem, NC 27157 (bfreedma@wakehealth.edu or clangefe@wakehealth.edu); or to Bruce A. Julian, MD,
Division of Nephrology, University of Alabama at Birmingham, THT 643, 1720 Second Avenue South, Birmingham, AL 35294
(bjulian@uab.edu); or to Robert P. Kimberly, MD, Division of Clinical Immunology/Rheumatology, University of Alabama at
Birmingham, Shelby Building, Room 172D, 1825 University Boulevard, Birmingham, AL 35294 (rpk@uab.edu).
Drs. Freedman and Langefeld contributed equally to this work. Drs. Julian and Kimberly contributed equally to this work.
Dr. Costenbader has received consulting fees, speaking fees, and/or honoraria from Biogen Idec and Genzyme (less than $10,000
each). Dr. Julian has received consulting fees from Astellas Pharma (less than $10,000).
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the
final version to be published. Dr. Freedman had full access to all of the data in the study and takes responsibility for the integrity of
the data and the accuracy of the data analysis.
Study conception and design. Freedman, Langefeld, Croker, Hebert, Hicks, Edberg, Brown, Reveille, Julian, Kimberly.
Acquisition of data. Freedman, Langefeld, Andringa, Croker, Garner, Birmingham, Hebert, Hicks, Segal, Edberg, Brown, Alarcón,
Costenbader, Criswell, Harley, James, Kamen, Lim, Merrill, Sivils, Niewold, Patel, Petri, Ramsey-Goldman, Reveille, Salmon, Tsao,
Gibson, Byers, Vinnikova, Lea, Julian, Kimberly.




Arthritis Rheumatol. Author manuscript; available in PMC 2014 April 28.
Published in final edited form as:






















Health Science Center at Houston 17Hospital for Special Surgery and Weill Cornell Medical
College, New York, New York 18University of California, Los Angeles 19University of North
Carolina at Chapel Hill 20Virginia Commonwealth University Medical Center, Richmond
Abstract
Objective—Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus
(SLE) that exhibits familial aggregation and may progress to end-stage renal disease (ESRD). LN
is more prevalent among African Americans than among European Americans. This study was
undertaken to investigate the hypothesis that the apolipoprotein L1 gene (APOL1) nephropathy
risk alleles G1/G2, common in African Americans and rare in European Americans, contribute to
the ethnic disparity in risk.
Methods—APOL1 G1 and G2 nephropathy alleles were genotyped in 855 African American
SLE patients with LN-ESRD (cases) and 534 African American SLE patients without nephropathy
(controls) and tested for association under a recessive genetic model, by logistic regression.
Results—Ninety percent of the SLE patients were female. The mean ± SD age at SLE diagnosis
was significantly lower in LN-ESRD cases than in SLE non-nephropathy controls (27.3 ± 10.9
years versus 39.5 ± 12.2 years). The mean ± SD time from SLE diagnosis to development of LN-
ESRD in cases was 7.3 ± 7.2 years. The G1/G2 risk alleles were strongly associated with SLE-
ESRD, with 25% of cases and 12% of controls having 2 nephropathy alleles (odds ratio [OR] 2.57,
recessive model P = 1.49 × 10−9), and after adjustment for age, sex, and ancestry admixture (OR
2.72, P = 6.23 × 10−6). The age-, sex-, and admixture-adjusted population attributable risk for
ESRD among patients with G1/G2 polymorphisms was 0.26, compared to 0.003 among European
American patients. The mean time from SLE diagnosis to ESRD development was ~2 years earlier
among individuals with APOL1 risk genotypes (P = 0.01).
Conclusion—APOL1 G1/G2 alleles strongly impact the risk of LN-ESRD in African
Americans, as well as the time to progression to ESRD. The high frequency of these alleles in
African Americans with near absence in European Americans explains an important proportion of
the increased risk of LN-ESRD in African Americans.
Systemic lupus erythematosus (SLE) is an auto-immune disorder with a markedly increased
prevalence among women and among individuals of African ancestry. Genome-wide
association studies (GWAS) have identified multiple susceptibility loci for SLE (1–6), as
well as for the presence of anti-RNA binding proteins (7) and anti–double-stranded DNA
antibodies (8). Lupus nephritis (LN) is a common and potentially severe complication of
SLE, which is initiated by immune complex deposition in the renal microvasculature. As
with SLE overall, African Americans have a higher prevalence of LN than European
Americans (9–11), with lack of equal access to care having often been suggested as a
contributing cause of the ethnic disparity in prevalence (12). Familial clustering of LN and
LN-associated end-stage renal disease (LN-ESRD) has been observed (13), suggesting that
genetic factors contribute not only to the risk of SLE but also to LN-ESRD. Risk alleles in
the Fcγ receptor and other genetic regions have been implicated in LN susceptibility (14–
16). A subset of individuals with LN ultimately develop progressive nephropathy or ESRD;
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thus, factors associated with progressive renal damage are of critical importance and remain
unknown.
Two coding alleles in the apolipoprotein L1 gene (APOL1), G1 and G2, are strongly
associated with several etiologies of progressive nondiabetic nephropathy in African
Americans, including focal segmental glomerulosclerosis (FSGS), human
immunodeficiency virus–associated collapsing glomerulopathy (HIVAN), hypertension-
attributed ESRD, focal global glomerulosclerosis with interstitial and vascular changes
(FGGS), and sickle cell nephropathy; ~12% of African Americans in the general population
have 2 risk alleles and are at heightened risk of nephropathy (17–20). These APOL1 alleles
are less strongly associated with mild forms of kidney disease (21–23), including LN
without progression to ESRD (24,25).
The role of alleles in APOL1 and other genes has not yet been studied in a large sample of
African Americans with LN-ESRD. Herein we report the results of a study by a national
consortium, in which APOL1-mediated genetic risk for LN-ESRD was compared in a
population-based sample of African American SLE cases who were receiving dialysis or had




African American subjects with SLE and LN-ESRD were identified through the
rheumatology, nephrology, and kidney transplant services of 18 academic referral centers,
the Center for Medicare and Medicaid Services, and via a validated query approach using
i2b2 (Informatics for Integrating Biology and the Bedside; based at Partners HealthCare
System, Boston, MA). Patients with LN-ESRD (cases) had a clinical diagnosis of SLE and
were either receiving dialysis or had undergone kidney transplantation. Additionally, cases
were required to have World Health Organization class III, IV, or V disease in the native
kidney, documented in a biopsy report (reviewed by one of the authors [BIF]) or 2)
nephropathy attributed to SLE by a physician based on clinical grounds or prior kidney
biopsy, documented in the medical record without an available pathology report. African
American controls were drawn from the PROFILE multicenter national consortium cohort
and had SLE without proteinuria, abnormal urinary sediment (casts), or renal biopsy
evidence of nephropathy (Systemic Lupus International Collaborating Clinics/American
College of Rheumatology criteria for kidney involvement) (26).
Genotyping
Two single-nucleotide polymorphisms (SNPs) in the APOL1 G1 nephropathy risk allele
(rs73885319 and rs60910145) and an indel for the G2 risk allele (rs71785313) were
genotyped in all cases and controls using a custom assay designed at the Wake Forest
School of Medicine Center of Genomics and Personalized Medicine on the Sequenom
platform. The G1 and G2 genotype calls were visually inspected for quality control.
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The individuals included in this analysis all passed the quality control analysis for an
ongoing GWAS for LN-ESRD, assessed using an Illumina chip (27). Admixture estimates
were computed using a linkage disequilibrium–pruned (r2 < 0.2) set of high-quality SNPs
(i.e., <5% missing genotype data, no differential missingness between cases and controls, no
significant deviation from Hardy-Weinberg equilibrium, no excess heterozygosity), and self-
reported and genotypic ancestry were consistent for all individuals in the analyses described
herein. Demographic characteristics were compared between LN-ESRD cases and SLE
controls using either logistic regression, linear regression, or Wilcoxon’s signed rank test.
Compound G1/G2 homozygotes were defined as individuals who were homozygous for the
G1 risk allele, homozygous for the G2 risk allele, or heterozygous for the G1 and G2 risk
alleles. To test for association between G1/G2 compound risk and LN-ESRD, a logistic
regression model was computed, with adjustment for age at SLE onset, sex, and admixture
proportion (computed using the program Admixture) (28). The corresponding GWAS
adjusted for these admixture estimates and using the same model as reported herein had an
inflation factor of 0.99. Thus, after adjustment for these admixture estimates, there is no
evidence of inflation of the tests of association. Because information on age at onset of SLE
was missing for a subset of cases, the analysis was repeated with adjustment for admixture
only; in this analysis the sample size could be maximized and the estimates of effect could
be directly compared. To meet the distributional assumptions of conditional normality and
homogeneity of variance for linear regression, age at SLE onset and duration from SLE
onset to ESRD onset were square root transformed when analyzed as the response variable.
To estimate the crude (unadjusted) attributable risk, we used the standard formula for case–
control designs:
where n0 and n1 denote the number of cases without and with the G1/G2 compound risk,
respectively, and m0 and m1 denote the number of controls without and with the G1/G2
compound risk, respectively; here, n0 + n1 = n. The odds ratio (OR)–based population
attributable risk (29), using the rare disease assumption, was computed as follows:
where b is the estimated proportion of individuals with the G1/G2 compound risk genotype.
RESULTS
The study sample comprised 1,389 African Americans with SLE (855 cases with LN-ESRD
and 534 non-nephropathy controls). The proportion of women in the sample was slightly
higher among controls than among cases (93% versus 88%; P = 0.0025) (Table 1),
consistent with the reported increased incidence of LN-ESRD in men (30). Eighty-five
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percent of the LN-ESRD cases had received cytotoxic therapy and 9% reported having a
first-degree relative with ESRD (data unavailable for SLE non-nephropathy controls). The
mean ± SD age at onset of SLE was 27.3 ± 10.9 years and 39.5 ± 12.2 years in cases and
controls, respectively (P = 4.21 × 10−42). The mean duration from SLE onset to ESRD onset
in cases was 7.3 ± 7.2 years. Among controls, the mean duration from SLE diagnosis to the
most recent encounter was 10.1 years.
More than 95% of the LN-ESRD cases had a diagnosis of hypertension. Diagnosis of LN
was based on available kidney biopsy report in 571 (66.8%) of the cases and review of
medical records in 284 (33.2%).
APOL1 G1/G2 genotypes varied based on ESRD status, as shown in Table 2. The African
admixture proportion was highest in individuals with 2 copies of the risk alleles for either
G1 or G2. Dichotomization of the study population into compound homozygotes for the risk
alleles versus heterozygotes and homozygotes for the wild-type allele (i.e., recessive genetic
model for risk alleles) revealed a significant association with LN-ESRD (Table 3). Without
adjustment for age, sex, and admixture proportion, the logistic model yielded an estimated
OR of 2.57 (95% confidence interval 1.89–3.50) for APOL1 association with LN-ESRD
(recessive model; P = 1.49 × 10−9). Adjustment for these covariates markedly reduced the
sample size but still yielded a highly significant association with LN-ESRD. In fact,
adjusting only for global measures of European American admixture in these samples
increased the magnitude of the effect to an OR of 2.80 and still yielded a highly significant
association (P = 2.21 × 10−8), despite reducing the sample size by 26%. Comparison of LN-
ESRD cases with and those without available kidney biopsy results revealed no statistically
significant differences in the APOL1 association (P = 0.90); specifically, the OR was 2.46
for LN-ESRD cases without an available kidney biopsy report and 2.54 in cases with a
kidney biopsy report.
From these estimates we could compute crude (unadjusted) and OR-based estimates of
attributable risk. In the African Americans, the crude estimate of attributable risk was 0.155.
Under the rare disease assumption and without adjustment for covariates, the OR-based
population attributable risk was 0.195. After adjustment for age, sex, and population
admixture estimates, the OR-based population attributable risk was 0.256. The latter
increase in the attributable risk estimate is consistent with the increase in the OR from 2.57
to 2.72 with adjustment for admixture estimates. The frequency of the G1/G2 risk genotype
is on the order of 0.002 in samples from European Americans. Assuming the same OR
(2.72), the same OR-based calculations suggest a G1/G2 attributable risk for LN-ESRD in
European Americans to be on the order of 0.0034. These estimates suggest that the
attributable risk is ~75 times greater in African Americans than in European Americans,
based purely on allele frequency.
If the G1/G2 alleles in APOL1 function as a progressor gene for lupus ESRD, one would
anticipate that, on average, the time to onset of ESRD would be reduced among individuals
with 2 copies of the risk alleles. Our data revealed a 2-year reduction in the time from
diagnosis of SLE to the onset of ESRD in this group (P = 0.01) (Table 4), representing a
26% shorter mean duration and a 33% shorter median duration compared with patients
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having 0 or 1 allele. Specifically, as the number of risk alleles increased, the duration of time
from SLE onset to ESRD onset decreased (mean ± SD 8.8 ± 7.8 years, 7.2 ± 6.8 years, and
5.8 ± 6.6 years among patients with no risk allele, 1 risk allele, and 2 risk alleles,
respectively; P for trend = 0.0004). After adjustment for admixture and ESRD status, there
was a weak trend toward individuals with 2 G1/G2 risk alleles having a modestly earlier age
at SLE diagnosis (P = 0.0840).
DISCUSSION
To our knowledge, this is the first report of an association between APOL1 nephropathy risk
alleles and severe LN with progression to ESRD in the high-risk African American
population. Although a large proportion of patients with SLE develop kidney involvement
(hematuria, proteinuria, and/or declining kidney function), most do not progress to
development of ESRD. There is strong evidence in support of the notion of an inherited
contribution to LN, including far higher rates of LN and LN-ESRD in populations with
African ancestry relative to European ancestry, and strong familial aggregation. Delineation
of genetic factors that lead to ESRD in patients with LN will likely enrich our understanding
of the etiology of progressive LN and improve risk prediction, and may ultimately yield
therapeutic targets to prevent progression to end-stage disease.
Because renal damage is one of the main predictors of mortality in SLE, the magnitude of
the impact of the APOL1 G1/G2 alleles on LN-ESRD is very important. The OR-based
attributable risk of 0.26 is greater than any individual such estimate for an SLE risk allele,
including any individual SNP allele in the major histo-compatibility complex. Given the
relative allele frequencies of the G1 and G2 risk alleles across various ethnicities, a large
proportion of the ethnic disparity in LN-ESRD burden among individuals of African descent
can be attributed to these alleles. Other factors contribute to this disparity as well, but
genetic factors, and specifically the APOL1 alleles, need to be taken into consideration in
studies that aim to more accurately characterize additional factors that might be targets for
intervention.
The findings reported herein are consistent with the hypothesis that the G1/G2 alleles in
APOL1 accelerate progression to ESRD (31). The difference of 2 years in the median time
from diagnosis of SLE to development of ESRD represents an important 33% shorter
median time from SLE onset to ESRD development in patients with versus those without the
risk G1/G2 genotype. Extensions of these data are relevant with regard to kidney
transplantation. The likelihood of donating a kidney to a relative with ESRD as opposed to
an unrelated individual is higher among African Americans than among European
Americans (32). Kidneys from deceased donors harboring 2 APOL1 nephropathy alleles
have been shown to fail more rapidly after transplantation than those from deceased donors
with 0 or 1 risk alleles (33).
Our data revealed that membranous, focal proliferative, and diffuse proliferative forms of
LN were more likely to progress to ESRD; only a few patients with the LN–collapsing
glomerulopathy lesion (34) were identified in our population-based series. In a previous
study of a small number of patients at Wake Forest School of Medicine, we detected
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association of the APOL1 gene with LN-ESRD, which we were unable to replicate after
including additional cases with milder (non-ESRD) forms of LN (24). The present study and
the study by Larsen et al (34) confirm that the association of alleles of the APOL1 gene with
LN is limited to the most aggressive forms that are more likely to progress to ESRD. This is
consistent with reports of patients with other nephropathies such as hypertension-attributed
disease and in population-based studies of African Americans (20–22).
We elected not to test specific histologic variants or subtypes of LN for an association
because renal lesions may change over time, renal biopsies were not interpreted by a single
pathologist, and 85% of the LN-ESRD cases had received cytotoxic therapy (treatment may
alter the findings on kidney biopsy). The exclusion of cases with physician-reported SLE
and ESRD with biopsy evidence of idiopathic FSGS, HIVAN, or other non–SLE-associated
kidney diseases from the analysis strengthens the likelihood of a true association.
Additionally, the consistent association results in individuals without available kidney
biopsy reports support the assumption that LN was the cause of their ESRD. We could not
assess the effect of renin–angiotensin–aldosterone system (RAAS) blockade on risk for
progression of LN; however, previous studies failed to demonstrate marked improvement in
progression of APOL1-associated nephropathy to ESRD with intensive blood pressure
control or RAAS inhibition (20).
In conclusion, this large population-based study of African American patients with LN
provides strong evidence of an association between LN-ESRD and the APOL1 G1 and G2
nephropathy risk alleles. These findings extend the spectrum of APOL1-associated non-
diabetic kidney disease by adding progressive LN to the list that already includes FSGS,
FGGS (hypertension attributed), HIVAN, and sickle cell nephropathy. Furthermore, our
results support the hypothesis that the G1 and G2 alleles of the APOL1 gene mediate
progression of LN, as the association with ESRD was stronger than previously described
associations with disease that was nonprogressive as manifested by mildly decreased kidney
function or modest albuminuria. Although the precise mechanism by which APOL1
contributes to development of severe nephropathy remains unknown, inhibition of the effect
of these genetic alleles may assist in slowing progressive renal injury in a broad spectrum of
nondiabetic kidney diseases, including LN.
Acknowledgments
Supported by NIH grants R01-DK-070941 and DK-084149 to Dr. Freedman; P01-DK-55546 and UL1-RR-025755
to Dr. Hebert; P60-AR-053308, K24-AR-02175, R01-AR-052300, and UL1-TR-000004 to Dr. Criswell;
AI-024717, AI-083194, AR-049084, and AR-042460 to Dr. Harley; U191082714, P30-AR-053483, P30-
GM-103510, and U01-AI-101934 to Dr. James and the Oklahoma Medical Research Foundation; P60-AR-062755
and UL1-RR-029882 to Dr. Kamen; R01-AR-060861, K08-AI-083790, P30-DK-42086, L30-AI-071651, and UL1-
RR-024999 to Dr. Niewold; R01-AR-043727 to Dr. Petri; K24-AR-002138, P60-AR-30692, and UL1-RR-025741
to Dr. Ramsey-Goldman; R01-AR-043814 to Dr. Tsao; RC2-AR-058951 and UL1-TR-000165 to Dr. Kimberly;
P01-AR-049084 to Dr. Kimberly and the PROFILE investigators (Drs. Edberg, Brown, Alarcón, Petri, Ramsey-
Goldman, and Reveille); and P01-AI-083194 to the International Consortium on the Genetics of Systemic Lupus
Erythematosus (SLEGEN). Additional support was provided by awards from the James D. Casto Research Fund (to
Dr. Hebert), the Alliance for Lupus Research (to Drs. Criswell and Niewold), the US Department of Defense
(PO094002 to Dr. Harley), the US Department of Veterans Affairs (to Dr. Harley), and the Lupus Research
Institute (to Dr. Niewold). Dr. Criswell is recipient of a Kirkland Scholar Award. The Hospital for Special Surgery
Registry and Repository is supported by the Mary Kirkland Center for Lupus Research.
Freedman et al. Page 7






















The authors thank staff of the Center for Public Health Genomics, Wake Forest School of Medicine for providing
computing support, and James Knox for conducting chart review, patient recruitment, and compilation of data from
the Birmingham patients.
References
1. Kozyrev SV, Abelson AK, Wojcik J, Zaghlool A, Linga Reddy MV, Sanchez E, et al. Functional
variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet.
2008; 40:211–6. [PubMed: 18204447]
2. Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, et al.
Genome-wide association scan in women with systemic lupus erythematosus identifies
susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008; 40:204–10.
[PubMed: 18204446]
3. Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, et al. Association of systemic
lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med. 2008; 358:900–9.
[PubMed: 18204098]
4. Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, Leon JM, et al. Genetic variants near
TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet. 2008; 40:1059–61.
[PubMed: 19165918]
5. Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, Hu Z, et al. Genome-wide association study in a
Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus.
Nat Genet. 2009; 41:1234–7. [PubMed: 19838193]
6. Yang W, Shen N, Ye DQ, Liu Q, Zhang Y, Qian XX, et al. Asian Lupus Genetics Consortium
(ALGC). Genome-wide association study in Asian populations identifies variants in ETS1 and
WDFY4 associated with systemic lupus erythematosus. PLoS Genet. 2010; 6:e1000841. [PubMed:
20169177]
7. Kariuki SN, Franek BS, Kumar AA, Arrington J, Mikolaitis RA, Utset TO, et al. Trait-stratified
genome-wide association study identifies novel and diverse genetic associations with serologic and
cytokine phenotypes in systemic lupus erythematosus. Arthritis Res Ther. 2010; 12:R151. [PubMed:
20659327]
8. Chung SA, Taylor KE, Graham RR, Nititham J, Lee AT, Ortmann WA, et al. Differential genetic
associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production. PLoS
Genet. 2011; 7:e1001323. [PubMed: 21408207]
9. Freedman BI, Wilson CH, Spray BJ, Tuttle AB, Olorenshaw IM, Kammer GM. Familial clustering
of end-stage renal disease in blacks with lupus nephritis. Am J Kidney Dis. 1997; 29:729–32.
[PubMed: 9159307]
10. National Institute of Diabetes and Digestive and Kidney Diseases. US Renal Data System, USRDS
2012 Annual Data Report. Vol. 1: Atlas of chronic kidney disease and end-stage renal disease in
the United States. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney
Diseases, NIH; 2012.
11. Richman IB, Taylor KE, Chung SA, Trupin L, Petri M, Yelin E, et al. European genetic ancestry is
associated with a decreased risk of lupus nephritis. Arthritis Rheum. 2012; 64:3374–82. [PubMed:
23023776]
12. Powe NR. To have and have not: health and health care disparities in chronic kidney disease.
Kidney Int. 2003; 64:763–72. [PubMed: 12846781]
13. Ramos PS, Brown EE, Kimberly RP, Langefeld CD. Genetic factors predisposing to systemic
lupus erythematosus and lupus nephritis. Semin Nephrol. 2010; 30:164–76. [PubMed: 20347645]
14. Karassa FB, Trikalinos TA, Ioannidis JP. FcγRIIIA-SLE Meta-analysis Investigators. . The
FcγRIIIA-F158 allele is a risk factor for the development of lupus nephritis: a meta-analysis.
Kidney Int. 2003; 63:1475–82. [PubMed: 12631364]
15. Quintero-Del-Rio AI, Kelly JA, Kilpatrick J, James JA, Harley JB. The genetics of systemic lupus
erythematosus stratified by renal disease: linkage at 10q22.3 (SLEN1), 2q34–35 (SLEN2), and
11p15. 6 (SLEN3). Genes Immun. 2002; 3 (Suppl 1):S57–62. [PubMed: 12215904]
Freedman et al. Page 8






















16. Quintero-Del-Rio AI, Kelly JA, Garriott CP, Hutchings DC, Frank SG, Aston CE, et al. SLEN2
(2q34–35) and SLEN1 (10q22. 3) replication in systemic lupus erythematosus stratified by
nephritis. Am J Hum Genet. 2004; 75:346–8. [PubMed: 15307049]
17. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, et al. Association of
trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010; 329:841–5.
[PubMed: 20647424]
18. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, et al. Missense mutations in the
APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the
MYH9 gene. Hum Genet. 2010; 128:345–50. [PubMed: 20635188]
19. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, et al. APOL1 genetic variants
in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;
22:2129–37. [PubMed: 21997394]
20. Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WH, et al. the
AASK Investigators. Apolipoprotein L1 gene variants associate with hypertension-attributed
nephropathy and the rate of kidney function decline in African Americans. Kidney Int. 2013;
83:114–20. [PubMed: 22832513]
21. Friedman DJ, Kozlitina J, Genovese G, Jog P, Pollak MR. Population-based risk assessment of
APOL1 on renal disease. J Am Soc Nephrol. 2011; 22:2098–105. [PubMed: 21997396]
22. Freedman BI, Langefeld CD, Turner J, Nunez M, High KP, Spainhour M, et al. Association of
APOL1 variants with mild kidney disease in the first-degree relatives of African American
patients with non-diabetic end-stage renal disease. Kidney Int. 2012; 82:805–11. [PubMed:
22695330]
23. Foster MC, Coresh J, Fornage M, Astor BC, Grams M, Franceschini N, et al. APOL1 variants
associate with increased risk of CKD among African Americans. J Am Soc Nephrol. 2013;
24:1484–91. [PubMed: 23766536]
24. Freedman BI, Edberg JC, Comeau ME, Murea M, Bowden DW, Divers J, et al. The non-muscle
myosin heavy chain 9 gene (MYH9) is not associated with lupus nephritis in African Americans.
Am J Nephrol. 2010; 32:66–72. [PubMed: 20523037]
25. Lin CP, Adrianto I, Lessard CJ, Kelly JA, Kaufman KM, Guthridge JM, et al. Role of MYH9 and
APOL1 in African and non-African populations with lupus nephritis. Genes Immun. 2012;
13:232–8. [PubMed: 22189356]
26. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation
of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus
erythematosus. Arthritis Rheum. 2012; 64:2677–86. [PubMed: 22553077]
27. Kimberly RP, Freedman BI, Langfeld CD, Absher D, Andringa KK, Birmingham D, et al. Lupus
Nephritis-ESRD Consortium. Apolipoprotein L1 risk variants underlie racial disparities in lupus
nephritis-induced end-stage renal disease [abstract]. Arthritis Rheum. 2012; 64 (Suppl):S313.
28. Alexander DH, Novembre J, Lange K. Fast model-based estimation of ancestry in unrelated
individuals. Genome Res. 2009; 19:1655–64. [PubMed: 19648217]
29. Coughlin SS, Benichou J, Weed DL. Attributable risk estimation in case-control studies. Epidemiol
Rev. 1994; 16:51–64. [PubMed: 7925727]
30. Schwartzman-Morris J, Putterman C. Gender differences in the pathogenesis and outcome of lupus
and of lupus nephritis. Clin Dev Immunol. 2012; 2012:604892. [PubMed: 22690240]
31. Palmer ND, Freedman BI. APOL1 and progression of nondiabetic nephropathy. J Am Soc
Nephrol. 2013; 24:1344–6. [PubMed: 23813212]
32. Reeves-Daniel A, Bailey A, Assimos D, Westcott C, Adams PL, Hartmann EL, et al. Donor–
recipient relationships in African American vs. Caucasian live kidney donors. Clin Transplant.
2011; 25:E487–90. [PubMed: 21504475]
33. Reeves-Daniel AM, DePalma JA, Bleyer AJ, Rocco MV, Murea M, Adams PL, et al. The APOL1
gene and allograft survival after kidney transplantation. Am J Transplant. 2011; 11:1025–30.
[PubMed: 21486385]
34. Larsen CP, Beggs ML, Saeed M, Walker PD. Apolipoprotein L1 risk variants associate with
systemic lupus erythematosus-associated collapsing glomerulopathy. J Am Soc Nephrol. 2013;
24:722–5. [PubMed: 23520206]
Freedman et al. Page 9











































Freedman et al. Page 10
Table 1
Characteristics of the SLE patients with ESRD (cases) and the SLE patients without nephropathy (controls)*
LN-ESRD cases (n = 855)†
SLE non-nephropathy controls (n =
534)† P‡
Female, no. (%) 749 (88) 465 (93) 0.0025
Age at recruitment, years 41.14 ± 11.66 (41) 41.5 ± 11.73 (42.4) 0.54
Age at ESRD development, years 33.82 ± 11.57 (33) NA NA
Age at SLE onset, years 27.27 ± 10.90 (25) 39.46 ± 12.21 (40) 4.21 ± 10−42
Time from SLE onset to ESRD, years 7.33 ± 7.19 (5) NA NA
African ancestry, proportion 0.83 ± 0.09 (0.85) 0.83 ± 0.09 (0.85) 0.61
No. of ACR SLE criteria (excluding renal criteria) met 4.36 ± 1.74 (4) 4.94 ± 1.07 (5) 1.59 ± 10−9
Hypertension, no. (%) 763 (96) NA NA
History of ESRD in first-degree relatives, no. (%) 62 (9) NA NA
Cytotoxic therapy, no. (%) 558 (85) NA NA
*
Except where indicated otherwise, values are the mean ± SD (median). SLE = systemic lupus erythematosus; ESRD = end-stage renal disease; LN
= lupus nephritis; NA = not applicable or not available; ACR = American College of Rheumatology.
†
 For some variables, n values were slightly lower due to missing data.
‡
 By Wilcoxon’s signed rank test (except for percent female [chi-square test]).
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Table 3
Results of test for association between APOL1 compound risk and LN-ESRD in patients with SLE*
Model (n, cases/controls) OR (95% CI) P
Unadjusted (855/534) 2.57 (1.89–3.50) 1.49 × 10−9
Adjusted for admixture (699/407) 2.80 (1.95–4.02) 2.21 × 10−8
Adjusted for age, sex, and admixture (494/283) 2.72 (1.76–4.19) 6.23 × 10−6
*
Compound risk is coded as a binary variable in which the risk genotypes are as follows: homozygous for the G1 allele, homozygous for the G2
allele, or compound heterozygous for G1/G2 (i.e., 2 copies of any risk allele). The frequency of G1/G2 compound heterozygosity was 0.25 among
LN-ESRD cases and 0.12 among SLE non-nephropathy controls. OR = odds ratio; 95% CI = 95% confidence interval (see Table 1 for other
definitions).
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